Document is current
Any future updates will be listed below
-
Authors
Planalp, Elizabeth M.
Langhough, Rebecca E.
Jonaitis, Erin M.
Van Hulle, Carol A.
Wilson, Rachael E.
Kollmorgen, Gwendlyn
Quijano-Rubio, Clara
Okonkwo, Ozioma C.
Bendlin, Barbara B.
Asthana, Sanjay
Blennow, Kaj
Zetterberg, Henrik
Johnson, Sterling C.
-
Funding
Funding for this research was provided by:
NIH (R01 AG027161)
NIH (R01 AG027161)
NIH (R01 AG027161)
NIH (R01 AG031790)
NIH (R01 AG027161)
NIH (R01 AG062167)
NIH (R01 AG037639)
NIH (P30 AG06715)
NIH (R01 AG027161)
- License Information
-
More Information
Article History
Received: 1 October 2024
Accepted: 26 May 2025
First Online: 3 June 2025
Declarations
:
: Competing interestsGGK is a full-time employee of Roche Diagnostics GmbH.CQR is a full-time employee of Roche Diagnostics International Ltd.HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).SCJ serves on advisory boards for ALZPath and Enigma Biomedical. EMP, RL, EJ, CAVH, REW, OCO, BB, SA, KJ report no competing interests.
